NCT06107400View on ClinicalTrials.gov

Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 8, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Alpha Thalassemia Hemoglobin H Constant SpringHemoglobinopathiesHereditary Diseases
Interventions
GENETIC

RM-004

Intravenous infusion of gene-edited CD34+autologous hematopoietic stem cells (RM-004) after myeloablative conditioning with busulfan.

Trial Locations (1)

Unknown

RECRUITING

The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, Nanning

All Listed Sponsors
collaborator

Guangzhou Reforgene Medicine Co., Ltd.

UNKNOWN

lead

The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army

OTHER